1. Introduction
1.1. Market Definition and Scope
1.2. Market Ecosystem
1.3. Currency and Limitation
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.2. Factor Analysis
4.3. Regulatory Analysis
4.3.1. North America
4.3.1.1. U.S.
4.3.1.2. Canada
4.3.2. Europe
4.3.3. Asia-Pacific
4.3.3.1. China
4.3.3.2. Japan
4.3.3.3. India
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter's Five Forces Analysis
4.4.1. Bargaining Power of Buyers
4.4.2. Bargaining Power of Suppliers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
5. Cancer/Tumor Profiling Market Assessment—by Biomarker Type
5.1. Overview
5.2. Genetic Biomarkers
5.3. Protein Biomarkers
6. Cancer/Tumor Profiling Market Assessment—by Cancer Type
6.1. Overview
6.2. Breast Cancer
6.3. Colorectal Cancer
6.4. Lung Cancer
6.5. Prostate Cancer
6.6. Lymphoma
6.7. Leukemia
6.8. Cervical Cancer
6.9. Other Cancer Types
7. Cancer/Tumor Profiling Market Assessment—by Technology
7.1. Overview
7.2. Next-Generation Sequencing (NGS)
7.3. Polymerase Chain Reaction (PCR)
7.4. In Situ Hybridization (ISH)
7.5. Immunohistochemistry (IHC)
7.6. Other Technologies
8. Cancer/Tumor Profiling Market Assessment—by Application
8.1. Overview
8.2. Research Applications
8.3. Clinical Applications
9. Cancer/Tumor Profiling Market Assessment—by End User
9.1. Overview
9.2. Pharmaceutical & Biopharmaceutical Companies
9.3. Hospitals & Diagnostic Laboratories
9.4. Academic & Research Institutes
9.5. Contract Research Organizations (CROs)
10. Cancer/Tumor Profiling Market Assessment—by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2022)
11.4.1. Thermo Fisher Scientific Inc. (U.S.)
11.4.2. Illumina, Inc. (U.S.)
11.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
11.4.4. Exact Sciences Corporation (U.S.)
11.4.5. Qiagen N.V. (Netherlands)
11.5. Competitive Dashboard
11.5.1. Industry Leaders
11.5.2. Market Differentiators
11.5.3. Vanguards
11.5.4. Emerging Companies
12. Company Profiles
12.1. Thermo Fisher Scientific, Inc.
12.2. Illumina, Inc.
12.3. Qiagen N.V.
12.4. F. Hoffmann-La Roche Ltd
12.5. Exact Sciences Corporation
12.6. Agilent Technologies, Inc.
12.7. NanoString Technologies, Inc.
12.8. HTG Molecular Diagnostics, Inc.
12.9. Agendia Inc.
12.10. Personalis, Inc.
12.11. Tempus Labs, Inc.
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Major Targeted Therapies and Corresponding Biomarkers
Table 2 Number of New Cancer Cases, by Type, 2020 Vs. 2030
Table 3 Regulatory Authorities Governing In Vitro Diagnostics, by Country/Region
Table 4 Global Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 5 Germline Mutations in Hereditary Cancer Syndromes: Cancer-Causing Genes as Biomarkers of Risk
Table 6 Global Cancer/Tumor Profiling Market for Genetic Biomarkers, by Country/Region, 2021-2030 (USD Million)
Table 7 Global Cancer/Tumor Profiling Market for Protein Biomarkers, by Country/Region, 2021–2030 (USD Million)
Table 8 Global Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD MILLION)
Table 9 Number of New Breast Cancer Cases Globally (2020–2035)
Table 10 Global Cancer/Tumor Profiling Market for Breast Cancer, by Country/Region, 2021–2030 (USD Million)
Table 11 Global Cancer/Tumor Profiling Market for Colorectal Cancer, by Country/Region, 2021–2030 (USD Million)
Table 12 Global Cancer/Tumor Profiling Market for Lung Cancer, by Country/Region, 2021–2030 (USD Million)
Table 13 Number of New Prostate Cancer Cases (2020–2035)
Table 14 Global Cancer/Tumor Profiling Market for Prostate Cancer, by Country/Region, 2021–2030 (USD Million)
Table 15 Number of New Non-Hodgkin Lymphoma Cancer Cases (2020–2035)
Table 16 Global Cancer/Tumor Profiling Market for Lymphoma, by Country/Region, 2021–2030 (USD Million)
Table 17 Estimated Number of New Leukemia Cases (2020–2035)
Table 18 Global Cancer/Tumor Profiling Market for Leukemia, by Country/Region, 2021–2030 (USD Million)
Table 19 Global Cancer/Tumor Profiling Market for Cervical Cancer, by Country/Region, 2021–2030 (USD Million)
Table 20 Number of New Cancer Cases (2020-2035)
Table 21 Global Cancer/Tumor Profiling Market for Other Cancer Types, by Country/Region, 2021–2030 (USD Million)
Table 22 Global Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 23 Global Next–Generation Sequencing (NGS) Cancer/Tumor Profiling Market, by Country/Region, 2021–2030 (USD Million)
Table 24 Global Polymerase Chain Reaction (PCR) Cancer/Tumor Profiling Market, by Country/Region, 2021–2030 (USD Million)
Table 25 Global In Situ Hybridization Cancer/Tumor Profiling Market, by Country/Region, 2021–2030 (USD Million)
Table 26 Applications of IHC in Oncology and Related Antibodies
Table 27 Global Immunohistochemistry (IHC) Cancer/Tumor Profiling Market, by Country/Region, 2021–2030 (USD Million)
Table 28 Global Other Technologies Cancer/Tumor Profiling Market, by Country/Region, 2021–2030 (USD Million)
Table 29 Global Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 30 Currently Available Targeted Therapies and Corresponding Biomarkers
Table 31 Global Cancer/Tumor Profiling Market for Research Applications, by Country/Region, 2021–2030 (USD Million)
Table 32 Frequently Used Clinical Tumor Markers
Table 33 Global Cancer/Tumor Profiling Market for Clinical Applications, by Country/Region, 2021–2030 (USD Million)
Table 34 Global Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 35 Global Cancer/Tumor Profiling Market for Pharmaceutical & Biopharmaceutical Companies, by Country/Region, 2021–2030 (USD Million)
Table 36 Global Cancer/Tumor Profiling Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 37 Global Cancer/Tumor Profiling Market for Academic & Research Institutes, by Country/Region, 2021–2030 (USD Million)
Table 38 Global Cancer/Tumor Profiling Market for CROs, by Country/Region, 2021–2030 (USD Million)
Table 39 Global Cancer/Tumor Profiling Market, by Region, 2021–2030 (USD Million)
Table 40 Estimated Cancer Cases in North America: 2020–2030
Table 41 North America: Cancer/Tumor Profiling Market, by Country, 2021–2030 (USD Million)
Table 42 North America: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 43 North America: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 44 North America: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 45 North America: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 46 North America: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 47 U.S.: Key Macro & Micro Indicators
Table 48 U.S.: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 49 U.S.: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 50 U.S.: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 51 U.S.: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 52 U.S.: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 53 Canada: Key Macro & Micro Indicators
Table 54 Canada: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 55 Canada: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 56 Canada: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 57 Canada: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 58 Canada: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 59 Europe: Cancer/Tumor Profiling Market, by Country, 2021–2030 (USD Million)
Table 60 Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 61 Europe: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 62 Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 63 Europe: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 64 Europe: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 65 Germany: Key Macro & Micro Indicators
Table 66 Germany: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 67 Germany: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 68 Germany: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 69 Germany: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 70 Germany: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 71 France: Key Macro & Indicators
Table 72 France: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 73 France: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 74 France: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 75 France: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 76 France: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 77 U.K.: Key Macro & Micro Indicators
Table 78 U.K.: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 79 U.K.: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 80 U.K.: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 81 U.K.: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 82 U.K.: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 83 Italy: Key Macro & Micro Indicators
Table 84 Italy: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 85 Italy: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 86 Italy: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 87 Italy: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 88 Italy: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 89 Spain: Key Macro & Micro Indicators
Table 90 Spain: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 91 Spain: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 92 Spain: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 93 Spain: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 94 Spain: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 95 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
Table 96 Rest of Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 97 Rest of Europe: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 98 Rest of Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 99 Rest of Europe: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 100 Rest of Europe: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 101 Asia-Pacific: Cancer/Tumor Profiling Market, by Country/Region, 2021–2030 (USD Million)
Table 102 Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 103 Asia-Pacific: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 104 Asia-Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 105 Asia-Pacific: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 106 Asia-Pacific: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 107 China: Key Macro & Micro Indicators
Table 108 China: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 109 China: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 110 China: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 111 China: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 112 China: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 113 Japan: Key Macro & Micro Indicators
Table 114 Japan: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 115 Japan: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 116 Japan: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 117 Japan: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 118 Japan: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 119 India: Key Macro & Micro Indicators
Table 120 India: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 121 India: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 122 India: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 123 India: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 124 India: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 125 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
Table 126 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 127 Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 128 Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 129 Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 130 Rest of Asia–Pacific: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 131 Latin America: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 132 Latin America: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 133 Latin America: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 134 Latin America: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 135 Latin America: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 136 Middle East & Africa: Cancer/Tumor Profiling Market, by Biomarker Type, 2021–2030 (USD Million)
Table 137 Middle East & Africa: Cancer/Tumor Profiling Market, by Technology, 2021–2030 (USD Million)
Table 138 Middle East & Africa: Cancer/Tumor Profiling Market, by Cancer Type, 2021–2030 (USD Million)
Table 139 Middle East & Africa: Cancer/Tumor Profiling Market, by Application, 2021–2030 (USD Million)
Table 140 Middle East & Africa: Cancer/Tumor Profiling Market, by End User, 2021–2030 (USD Million)
Table 141 Recent Developments, by Company, 2020-2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Cancer/Tumor Profiling Market, by Biomarker Type, 2023 Vs. 2030
Figure 8 Global Cancer/Tumor Profiling Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 9 Global Cancer/Tumor Profiling Market, by Cancer Type, 2023 Vs. 2030
Figure 10 Global Cancer/Tumor Profiling Market, by Application, 2023 Vs. 2030
Figure 11 Global Cancer/Tumor Profiling Market, by End User, 2023 Vs. 2030
Figure 12 Global Cancer/Tumor Profiling Market, by Geography, 2023 Vs. 2030
Figure 13 Global Cancer/Tumor Profiling Market: Impact Analysis of Market Drivers, Restraints, Opportunities, and Challenges (2023–2030)
Figure 14 Number of Cancer Cases, by Region, 2020
Figure 15 Pharmaceutical R&D Expenditures in The U.S., Europe, And China, 2010 Vs. 2019 Vs. 2020 (USD Million)
Figure 16 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 17 Percentage of Approved Personalized Medicines, by Disease, 2022
Figure 18 Percentage of FDA Approvals for Personalized Medicines, 2015–2022
Figure 19 Percentage of Oncology Trials Incorporating Biomarkers, 2000–2019
Figure 20 Global Increase in The Number of Personalized Medicines, 2008–2020
Figure 21 USFDA Regulatory Pathways for IVD Kits
Figure 22 EU Regulatory Pathway - IVDR 2017/746
Figure 23 China: Medical Device Classification and Premarket Requirements for Cancer/Tumor Profiling Products
Figure 24 Porter's Five Forces Analysis
Figure 25 Global Cancer/Tumor Profiling Market, by Biomarker Type, 2023 Vs. 2030 (USD Million)
Figure 26 Global Cancer/Tumor Profiling Market, by Cancer Type 2023 Vs. 2030 (USD Million)
Figure 27 Global Cancer/Tumor Profiling Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 28 Global Cancer/Tumor Profiling Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 29 FDA Approvals for Personalized Medicine (%) (2015–2021)
Figure 30 Global Cancer/Tumor Profiling Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 31 Global Pharmaceutical R&D Spending, 2014–2028 (USD Billion)
Figure 32 Global Cancer/Tumor Profiling Market, by Geography, 2023 Vs. 2030 (USD Million)
Figure 33 North America Cancer/Tumor Profiling Market Snapshot
Figure 34 U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion)
Figure 35 Europe: Pharmaceutical Industry R&D Expenditure (2000–2021)
Figure 36 Europe: Cancer/Tumor Profiling Market Snapshot
Figure 37 U.K: Number of Cancer Cases, 2010–2030 (In Million)
Figure 38 Italy: Ovarian Cancer Diagnoses (2018–2020)
Figure 39 Italy: Number of Biotechnology Firms, 2010-2021
Figure 40 Rest of Europe: Pharmaceutical R&D Expenditure, 2020
Figure 41 Asia-Pacific: Cancer/Tumor Profiling Market Snapshot
Figure 42 Japan: New Cancer Cases Reported (2020–2040)
Figure 43 Latin America: Estimated Number of New Cancer Cases (2020–2030)
Figure 44 Middle East & Africa: Number of New Cancer Cases, by Country/Region (2020)
Figure 45 Key Growth Strategies Adopted by Leading Players, 2020– 2023
Figure 46 Cancer/Tumor Profiling Market: Competitive Benchmarking by Offering
Figure 47 Cancer/Tumor Profiling Market: Competitive Benchmarking by Technology
Figure 48 Cancer/Tumor Profiling Market: Competitive Benchmarking, by Region
Figure 49 Global Cancer/Tumor Profiling Market Share Analysis, by Key Players, 2022 (%)
Figure 50 Competitive Dashboard: Cancer/Tumor Profiling Market
Figure 51 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 52 Illumina, Inc.: Financial Overview (2022)
Figure 53 Qiagen N.V.: Financial Overview (2022)
Figure 54 F. Hoffmann-La Roche Ltd: Financial Overview (2022)
Figure 55 Exact Sciences Corporation: Financial Overview (2022)
Figure 56 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 57 NanoString Technologies, Inc.: Financial Overview (2022)
Figure 58 HTG Molecular Diagnostics, Inc.: Financial Overview (2022)
Figure 59 Personalis, Inc.: Financial Overview (2022)
COVID-19
This report provides pre & post COVID-19 market estimates.